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OBJECTIVES: To estimate the amount of assistance caregivers
(CG) of mild to moderate Alzheimer’s Disease (AD) patients must
provide in a typical day, and to compare those estimates across
varying levels of cognition, function or behavior. METHODS:
Observational study of 180 patients with mild to moderate AD.
Patients were required to have a study partner (CG) who spent at
least 10 hours perweekwith the patient. These results represent an
initial analysis of 82 patients enrolled as of January 2007. Esti-
mates of time spent assisting with basic activities of daily living
(ADL), instrumental activities (IADL) and supervision during the
previous month were collected using the Resource Use in Demen-
tia (RUD)-Lite version 2.3. Total CG time (sum of ADL, IADL,
supervision) was assessed across varying levels of cognition (Mini-
Mental State Examination, MMSE), function (Disability Assess-
ment of Dementia, DAD), and neuropsychiatric symptoms
(Neuropsychiatric Inventory, NPI). RESULTS: Mean patient age
was 76.0 years (SD = 6.38), compared to 70.9 years (SD = 11.26)
for caregivers. Caregivers were typically the patient’s spouse
(74.4%), 56.1% were female, and 75.0% were the sole caregiver.
Over one in ﬁve CG (18/82) provided more than 8 hours of
care/day; support with IADL and supervision accounted for the
majority of this time. patients with mild AD (MMSE > 21)
required a median (mean +/- SD) 1.6 (3.7 +/- 5.74) hours of CG
time/day vs 5.9 (8.2 +/- 7.93) hours/day for moderate AD patients
(MMSE 15–21), with much of the difference due to IADL and
supervision time. Worsening functional (r2 = 0.19, p < 0.0001)
and neuropsychiatric status (r2 = 0.10, p = 0.005) were also asso-
ciated with increased CG time. CONCLUSION: Mild to Moder-
ate AD is associated with signiﬁcant time burdens for caregivers,
with 20% of patients in this study requiring as much as or more
than a full working day of support.
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OBJECTIVES: To compare outcomes among multiple sclerosis
(MS) patients treated with either glatiramer acetate injection
(Copaxone) or High-Dose Interferon Beta 1-a (Rebif).
METHODS: Data from September 2001 to June 2006 were
obtained from i3’s Lab Rx Database. An “intent-to-treat” (ITT)
cohort (N = 845) was created of patients diagnosed with MS
who initiated therapy on one of two disease-modifying drugs
(DMD), either Copaxone or Rebif, and had continuous insur-
ance coverage from 6 months prior through 24 months post
medication initiation. A “continuous use” (CU) cohort (N = 410)
was created where individuals were required to have used the
medication of interest within 28 days of the end of the two year
post-period. Multivariate regressions were used to examine the
association between use of each DMD and two-year total direct
medical costs or relapse, where relapse was deﬁned as being
hospitalized with a diagnosis of MS or an outpatient visits with
a diagnosis of MS followed by a prescription for steroids within
a seven day period. All regressions controlled a wide range of
factors that may potentially impact outcomes. RESULTS: In the
ITT cohort, compared to those who initiated therapy on Rebif,
patients who initiated therapy on Copaxone had a signiﬁcantly
lower risk of relapse (Odds Ratio = 0.543; P = 0.0305) as well as
signiﬁcantly lower two-year total direct medical costs ($41,786 v
$49,030, P = 0.0002). In the CU cohort, compared to those who
used Rebif, patients who used Copaxone also had a signiﬁcantly
lower risk of relapse (Odds Ratio = 0.213; P = 0.0049) as well as
signiﬁcantly lower two-year total medical costs ($45,213 v
$57,311; P < 0.0001). CONCLUSION: Results from this study
indicate that compared to Rebif, use of Copaxone is associated
with signiﬁcantly lower odds of relapse as well as signiﬁcantly
lower total direct medical costs. These results are more pro-
nounced among patients deﬁned as “continuous users.”
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OBJECTIVES: Investigate the trends in Anti-alzheimer’s
medication utilization and associated patient characteristics
and generate annualized estimates at country-level, in Spain.
METHODS: AlzheimerMonitor is a multi-year annual study
conducted among neurologists/psychiatrists/geriatricians to
collect chart data on patients with AD diagnosis and/or docu-
mented anti-alzheimer’s medication use. 2005 & 2006 data on
patient demographics, disease severity and medication utilization
were used for this analysis to assess trends. A multi-stage weight-
ing method at physician/patient level was employed to extrapo-
late data to Spain population. RESULTS: Over 3100 patient
charts were abstracted each year by over 170 specialists from
diverse settings in 2005 & 2006; 71,184 & 80,510 patients were
estimated to have AD and/or have used anti-alzheimer’s medica-
tions in Spain in 2005 & 2006; 50,470 (71%) & 62,658 (78%)
had conﬁrmed AD diagnosis in 2005 & 2006, while the rest had
diagnosis of other dementias. Overall medication utilization
included (not mutually exclusive): AD-medications (2005:90%,
2006:88%), antipsychotics (2005:10%, 2006:12%), anti-
depressants (2005:7%, 2006:8%), anxiolytics (2005/2006:
5%), hypnotics/sedatives (2005/2006: 3%), psychostimulants/
neroptropics (2005:4%, 2006:1%). AD-medication utilization
trends (not mutually exclusive) among all patients included
(2005/2006, % patients): donepezil (40%/38%), memantine
(22%/27%), rivastigmine (24%/25%) and galantamine (21%/
22%). Among patients with AD diagnosis, average age was
76 yrs (2005/2006); AD severity distribution (2005/2006, %
patients) was—mild: 17.7%/21.3%, moderate: 44.2%/45.1%,
moderately-severe: 23.1%/24.5%, severe: 14.4%/8.6%. 86%
(2005) & 88% (2006) of AD-patients were treated with anti-
alzheimer’s medications; utilization in this group included:
donepezil (2005:40%, 2006:38%), memantine (2005:22%,
2006:27%), rivastigmine (2005:24%, 2006:25%) and galan-
tamine (2005:21%, 2006:22%). CONCLUSION: More than
two-third of anti-alzheimer’s medication users had AD diagnosis
and this group size increased from 2005 to 2006, primarily in the
mild/moderate disease categories. In contrary, at least one-in-ten
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